Results From Pharma Participants

A.Participant Metrics

B.Does your company already have a preferred alternative to the term "Key Opinion Leader / KOL" which you are required to use?

C.Instead of using the term "Key Opinion Leader" when referring to important physicians with high levels of expertise, experience, etc. (i.e. the generally accepted definition of a KOL), what term do you think should be used?

D.There were a large number of (some quite passionate!) comments on this issue. These are summarised into the following key points for further debate and discussion…

E.Should all Pharma companies (and other relevant stakeholders) work towards using one universal replacement for the term "KOL" going forwards, rather than each company adopting their own replacement terminology and definitions?

F. There were a large number of comments on this issue as well. These are summarised into the following key points for further debate and discussion…

Thank you so much to all those who participated! Please do not hesitate to contact us if you require a more detailed presentation, including an in-depth comparison of both surveys (Pharma and Expert/KOL) highlighting opportunities and areas of concern. We should probably repeat this survey in a few years to see if
things really have changed…

Results From KOL Participants

A.Participant Metrics

B.Instead of using the term "Key Opinion Leader" (KOL) when referring to important physicians with high levels of expertise, experience, etc (i.e. the generally accepted definition of a KOL), what term do you think should be used?

C.There were a very large number of comments on this issue. These are summarised into the following key points for further debate and discussion… (some comments are un-publishable!)

D.Instead of each Pharma company adopting their own replacement terminology and definition, should all Pharma companies and other relevant stakeholders work towards using one universal transparent replacement for the term "KOL" going forwards?

E.There were some comments on this issue. These are summarised into the following key points for further debate and discussion…

Thank you so much to all those who participated! Please do not hesitate to contact us if you require a more detailed presentation, including an in-depth comparison of both surveys (Pharma and Expert/KOL) highlighting opportunities and areas of concern. We should probably repeat this survey in a few years to see if
things really have changed…